PatentJun 8, 2026, 08:31 AM
CorMedix Wins Federal Circuit Appeal on MINOCIN® Patent Infringement
AI Summary
CorMedix announced that the U.S. Court of Appeals for the Federal Circuit affirmed the validity and infringement of its MINOCIN® for Injection patents by Nexus Pharmaceuticals, Inc. This decision upholds a prior district court ruling from 2023 and rejects Nexus' invalidity challenge. The Federal Circuit also affirmed a permanent injunction, preventing Nexus from marketing its generic minocycline product before patent expiration, thereby protecting CorMedix's innovative intravenous minocycline therapy.
Key Highlights
- Federal Circuit affirmed MINOCIN® for Injection patent validity and infringement.
- Decision upholds U.S. District Court's 2023 ruling in favor of CorMedix subsidiary.
- Federal Circuit rejected Nexus Pharmaceuticals' patent invalidity challenge.
- Permanent injunction against Nexus' generic minocycline product affirmed.
- Injunction bars Nexus from marketing generic prior to patent expiration.
- MINOCIN® patents are FDA Orange Book listed, protecting intravenous minocycline.
Price Impact
More from CRMD